Post COVID-19
Conditions
Keywords
Montelukast, cough, cough severity
Brief summary
As of September 2020, the COVID-19 pandemic has affected millions of people in 196 countries and left hundreds of thousands dead. After recovery it was found that up to 32% of cases had 1 or 2 symptoms, 55% had 3 or more Post-COVID-19 symptoms, and persistent Post COVID-19 cough was recorded in 29.3% of cases in one study. A recent study identified Montelukast, among the top-scoring clinically-oriented drugs likely to inhibit SARS-CoV-2 main protease. Besides its known effect that is reported to improve cough and prevent exercise-induced bronchoconstriction in asthma, many trials assessed Montelukast in the treatment of post-infectious cough and found variable effects. Despite that the exact mechanism is not yet identified, Barré and colleagues proposed several properties of Cyst LT1 receptor antagonists that are potentially beneficial in COVID-19.
Interventions
intervention group received standard cough therapy+ Montelukast 10 mg/day for 14 days
Sponsors
Assiut University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with Post COVID-19 persistent cough after 4 weeks of acute attack
Exclusion criteria
* Any contraindication to Montelukast, respiratory, cardiac disease, pregnancy, breastfeeding and use of angiotensin converting enzyme inhibitors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cough severity index | 14 days | Scale from mild to severe |
| Cough severity visual analog | 14 days | Severity from 0-10 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Side effects of drug | 14 days | Nausea, vomiting, abdominal pain, restlessness, depression |
Countries
Egypt
Outcome results
None listed